COVID-19 in Severe Asthma Network in Italy (SANI) patients:
clinical features, impact of comorbidities and treatments
Short title: COVID-19 and severe asthma in real-life
Enrico Heffler 1,2; Aikaterini Detoraki3; Marco Contoli 4; Alberto Papi4; Giovanni Paoletti 1,2; Giacomo
Malipiero 1; Luisa Brussino 5;
Claudia Crimi 6; Daniela Morrone 7;
Marianna Padovani 4; Giuseppe Guida8; Alberto Giovanni Gerli 9; Stefano
Centanni 10; Gianenrico Senna 11;
Pierluigi Paggiaro 12; Francesco Blasi13,14; Giorgio Walter Canonica 1,2on behalf of SANI Working Group *
1 Personalized Medicine, Asthma and Allergy -
Humanitas Clinical and Research Center IRCCS - Rozzano (MI), Italy
2 Department of Biomedical Sciences – Humanitas
University – Pieve Emanuele (MI), Italy
3 Department of Internal Medicine, Clinical
Immunology, Clinical Pathology and Infectious Disease, Azienda
Ospedaliera Universitaria Federico II, Napoli, Italy.
4 Department of Morphology, Surgery and Experimental
Medicine - University of Ferrara – Ferrara, Italy.
5 Department of Medical Sciences, AO Ordine Mauriziano
Umberto I – University of Torino - Torino, Italy.
6 Department of Clinical and Experimental Medicine -
University of Catania - Catania, Italy.
7 Severe Asthma Network in Italy (SANI) infrastructure
– Milano, Italy
8 Allergy and Pneumology Unit - A.O. S. Croce e Carle
– Cuneo, Italy.
9 Management Engineering Tourbillon Tech srl - Padova,
Italy.
10 Respiratory Unit, ASST Santi Paolo e Carlo, San
Paolo Hospital, Department of Health Sciences – University of Milano -
Milano, Italy.
11 Asthma Center and Allergy Unit - Verona University
Hospital - Verona, Italy.
12 Department of Surgery, Medicine, Molecular Biology
and Critical Care - University of Pisa - Pisa, Italy.
13 Internal Medicine Department – Respiratory Unit
and Adult Cystic Fibrosis Center – Fondazione IRCCS Cà Granda Ospedale
Maggiore Policlinico - Milano, Italy.
14 Department of Pathophysiology and Transplantation
– University of Milano – Milano, Italy
* SANI Working Group: Bonavia M., Bucca C., Caiaffa
MF., Calabrese C., Camiciottoli G., Caruso C., Conte ME., Corsico AG.,
Cosmi L., Costantino MT., Crimi N., D’Alò S., D’Amato M., Del Giacco S.,
Farsi A., Favero E., Foschino BMP., Guarnieri G., Lo Cicero S., Lombardi
C., Macchia L., Mazza F., Menzella F., Milanese M., Montuschi P.,
Montagni M., Nucera E., Parente R., Passalacqua G., Patella V., Pelaia
G., Pini L., Puggioni F., Ricciardi L., Ricciardolo FLM., Richeldi L.,
Ridolo E., Rolla G., Santus P., Scichilone N., Solidoro P., Spadaro G.,
Vianello A., Viviano V., Yacoub MR., Zappa MC.
Corresponding Author:
Prof. Enrico Heffler
Personalized Medicine, Asthma and Allergy
Istituto Clinico Humanitas
Via Alessandro Manzoni 56
20089 – Rozzano (MI) – Italy
Tel: +39 0282247013
Fax: + 39 0282246484
Email:enrico.heffler@hunimed.eu
Conflict of interest statements:
- Enrico Heffler reports participation to advisory boards and personal
fees from AstraZeneca, Sanofi, GSK, Novartis, Circassia, Nestlè
Purina, Boheringer Ingheleim, Valeas, outside the submitted work;
- Aikaterini Detoraki does not have any conflict of interest to report
- Marco Contoli reports grants from Chiesi, University of Ferrara –
Italy, personal fees from Chiesi, AstraZeneca, Boehringer Ingelheim,
Alk-Abello, GlaxoSmithKline, Novartis, Zambon, outside the submitted
work
- Alberto Papi reports grants, grants, personal fees and non-financial
support from AstraZeneca, Menarini, grants, personal fees,
non-financial support and other from Boehringer Ingelheim, Chiesi
Farmaceutici, TEVA, personal fees, non-financial support and other
from GlaxoSmithKline, Mundipharma, Zambon, Novartis, Sanofi/Regeneron,
personal fees from Roche, Edmondpharma, grants from Fondazione
Maugeri, Fondazione Chiesi, outside the submitted work.
- Giovanni Paoletti does not have any conflict of interest to report
- Giacomo Malipiero does not have any conflict of interest to report
- Luisa Brussino does not have any conflict of interest to report
- Claudia Crimi reports personal fees from Menarini.
- Daniela Morrone does not have any conflict of interest to report
- Marianna Padovani does not have any conflict of interest to report
- Giuseppe Guida does not have any conflict of interest to report
- Alberto Giovanni Gerli does not have any conflict of interest to
report
- Stefano Centanni reports personal fees from GLAXOSMITHKLINE, NOVARTIS,
MENARINI SPA, GUIDOTTI MALESCI, and grants and personal fees from
CHIESI SPA, ASTRA ZENECA, VALEAS, BOEHRINGER INGELHEIM, outside the
submitted work
- Gianenrico Senna does not have any conflict of interest to report
- Pierluigi Paggiaro reports grants and personal fees from AstraZeneca,
Chiesi, Novartis and Sanofi, and personal fees from GlaxoSmithKline,
Guidotti, Mundipharma, outside the submitted work
- Francesco Blasi reports grants and personal fees from Astrazeneca,
Chiesi, GSK, Pfizer and Insmed, grants from Bayer, and personal fees
from Guidotti, Grifols, Menarini, Mundipharma, Novartis and Zambon,
outside the submitted work
- Giorgio Walter Canonica reports grants as well as lecture or advisory
board fees from: A. Menarini, Alk-Abello, Allergy Therapeutics,
AstraZeneca, Boehringer-Ingelheim, Chiesi Farmaceutici, Genentech,
Guidotti-Malesci, Glaxo Smith Kline, Hal Allergy, Mylan, Merck,
Mundipharma, Novartis, Regeneron, Sanofi-Aventis, Sanofi-Genzyme,
StallergenesGreer, UCB pharma, Uriach Pharma, Valeas, ViborPharma
Funding statement: SANI is supported through unrestricted grants by
AstraZeneca, Glaxo Smith Kline, Novartis & Sanofi Genzyme
Aknowledgements :
We are grateful to Silvia Rabotti, Concetta Sirena & the SANI staff for
the invaluable work in managing the network.